China proposes changes to drug trial and API importation laws

By Gareth Macdonald

- Last updated on GMT


Related tags Small molecule drugs Clinical trial

Chinese regulators have proposed changes to rules covering clinical trials, API importation and drug approval in a bid to improve access to medicines.

The proposed changes – outlined in a draft guidance document issued by the China Food and Drug Administration (CFDA) on March 17 (here​ in Mandarin) – are designed to meet shorten clinical trial and approval times to meet “public demand for new drugs​.”

At present drugs can only be tested in China must if they have already gone through late stage studies (Phase II or III) or have been approved elsewhere. The new guidance would remove this requirement, enabling Chinese sites to be included in multi-centre studies.

Another proposal would allow foreign drug manufacturers with operations in China to import small molecule drugs and biologics before the product has been approved. Currently, imported drugs need to be approved in at least one market.

The CFDA also suggested drug firm’s whose multi-centre trials include a Chinese site should be allowed seek approval as soon as the study is completed.

The agency also said it plans to simplify registration rules for drugs that have been examined in multi-centre trials and waive trial registration requirements for subsequent China-based studies of such products.

The CFDA called for feedback on the proposed rule changes.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us


View more